Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A.
Sepúlveda-Sánchez JM, et al. Among authors: ruano y.
Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105.
Neuro Oncol. 2017.
PMID: 28575464
Free PMC article.
Clinical Trial.